EUCTR2017-003258-18-BE进行中（未招募）1 期
A randomized controlled trial to evaluate the short-term efficacy and long-term health economic impact of a dietary intervention compared to pharmacotherapy with a musculotropic spasmolytic agent for newly diagnosed or newly treated irritable bowel syndrome in primary care. - The DOMINO trial: Diet Or Medication in Irritable bowel syNdrOme
niversity Hospital Leuven0 个研究点目标入组 470 人开始时间: 2018年1月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 470
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Eligible patients are those of either gender, above the age of 18, eligible to give informed consent, newly diagnosed with or newly to be treated for IBS in primary care, as this is the setting where the majority of these patients is managed. The diagnostic gold standard, in line with clinical practice, will be clinician’s diagnostic judgment. However, to support the diagnosis and make it more uniform, a Rome IV-based diagnostic questionnaire with pictograms and a list of alarm symptoms will also be included in the CRF at the initial visit, and guidance for diagnosis and potentially useful additional tests will be provided at the investigator meetings, based on the Rome IV management algorithm. Patients who did not receive treatment over the preceding 4 months, and who did not receive long-term treatment (>3 consecutive weeks) with otilonium bromide in the past are eligible for the trial. Women with active pregnancy plans in the coming 6 months are not eligible and women of childbearing potential are only eligible if they use effective contraception throughout the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 470
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria applies to the following points:
- •Patients not capable to understand or be compliant with the study.
- •Patients with concurrent organic gastrointestinal disease (inflammatory bowel disease), a history of major bowel surgery (not including minimal invasive surgery such as appendectomy or cholecystectomy, but including sigmoidectomy, hemicolectomy and small bowel resections)
- •Patients who received treatment with otilonium bromide in the past for more than 3 weeks consecutively or who received otilonium bromide recently for any duration in the last 3 months.
- •Patients who have used FODMAP or NICE diet before.
- •Patients who recently (last 3 weeks) used other medication for IBS, or who changed their diet for IBS or for any other reason over the last 3 months. To be included in the trial patients should stop these treatments following the advice of their GP (see paragraph 8.9).
- •Patients with diabetes, uncontrolled thyroid disease, active malignant disease (not including patients with cancer free diagnosis for more than 5 years), symptomatic uncontrolled endometriosis.
- •Patients with a major psychiatric disease. The use of a single antidepressant on a stable dose for at least 3 months is allowed (see paragraph 8.9).
- •Patients with drug abuse and/or alcohol abuse.
- •Patients on pharmacologically prepared probiotic formulations (i.e. bought in the pharmacy) will be excluded. The use of probiotic drinks or yoghurts available from food stores, such as Activia®, Yakult ®, Actimel ®, is allowed but should be registered as complementary treatment”(see paragraph 8.9).
- •Women with active pregnancy plans in the coming 6 months are not eligible and women of childbearing potential are only eligible if they use effective contraception throughout the study. Also excluded are women of childbearing potential not using effective contraception or women planning to become pregnant the next 6 months (see paragraph 8.9 of the protocol). Methods of contraception considered highly effective are: combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, a vasectomized partner or sexual abstinence (http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf).
研究者
相似试验
已完成
不适用
Short version life review intervention for palliative patientsSpiritual wellbeing in palliative care patientsMental and Behavioural DisordersISRCTN50078329The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong102
已完成
不适用
Simplified Management of Obstructive Sleep Apnea in General PracticeObstructive sleep apneaRespiratory - Sleep apnoeaACTRN12608000514303ational Health and Medical Research Council250
已完成
不适用
Worksite intervention effects on psychological and physical health: A randomised controlled trialDepressive, anxious, and stress symptoms,Self-rated sleep qualityQuality-of-life outcomes,Physical healthMental Health - DepressionMental Health - Studies of normal psychology, cognitive function and behaviourACTRN12605000110684niversity of Sydney70
招募中
2 期
An experimental study to see if along with routine pain medications, soft music played during the process of egg (oocyte) pick up for infertility treatment is beneficial for pain relief.CTRI/2020/09/027519FLUID Research Grant
已完成
不适用
Randomized, controlled trial of the effect of short-term co-administration of methylcobalamin and folate on serum asymmetric dimethylarginine (ADMA) concentration in patients receiving long-term hemodialysis.Chronic kidney disease (CKD)JPRN-UMIN000002776Department of Nephrology, Kariya-Toyota General Hospital40